Prescient Therapeutics PTX, Novel Cancer Therapies

$PTX is a clinical stage oncology company developing personalised medicine approaches to cancer, including cellular and targeted therapies.

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics (ASX:PTX) is pleased to announce the appointment of Dr Rosalind Wilson as Chief Medical Officer. Read more 👉 https://t.co/IHJxIPvg5z

“I look forward to working with the team to advance these programs and unlock their full potential,” said Dr Wilson.

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics (ASX:PTX) CEO, James McDonnell recently discussed Prescient's collaboration with CSIRO. Watch now ▶ ️https://t.co/pSZivz0D9q

🔗 Stay up-to-date on Prescient’s news and announcements: https://t.co/lh2f54kXav

#Biotech #CancerTherapies #CancerTreatment

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics (ASX: PTX) recently held an insightful Investor Briefing with CEO, James McDonnell. James discussed why the FDA has fast tracked PTX-100, how our first-in-class technology could apply to 22% of all cancer cases, and more. Watch now: https://t.co/y36djk69z3

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics (ASX: PTX) is pleased to provide its Activities Report and Appendix 4C for the quarter ended 31 March 2026. CEO, James McDonnell will host an Investor Briefing on 5 May at 12pm (AEST). Register 🔗 https://t.co/PqtRNLkvxF

#Biotech #Health #CancerTreatment

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics (ASX: PTX) is pleased to release an update for the quarter ending 31 December 2025. James McDonnell will be hosting an Investor Briefing on 4th February at 11am (AEDT). Register 🔗 https://t.co/MUlxWDvD99

View announcement 🔗 https://t.co/xpf04mWryL

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

As we begin an exciting new year, Prescient Therapeutics (ASX: PTX) CEO, James McDonnell, caught up with @proactive_au to discuss what investors can expect in 2026. Watch now 👉 https://t.co/GuohqmkPur

🔗 Stay up-to-date on news: https://t.co/huln688Vhs

#Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Special Report 📣 $PTX has raised $3m in a placement to sophisticated and professional investors following a $6.8m SPP for a total $9.8m to advance its pioneering cancer treatment therapy.

Read more 👉 https://t.co/OQbyX9hMSc

#Biotech #Health

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics $PTX is pleased to provide its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2025 quarter.
View the announcement 👉 https://t.co/Eb0m0taVaw

#Biotech #Health #CancerTherapies #CancerTreatment

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Special Report📣 $PTX has entered a critical stage where clinical data, regulatory support & commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market.
Read more @australian👉https://t.co/xX6boUZ0dN

#Health #Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Gain insights on Prescient’s advanced cancer drug PTX-100, which is in its all-important Phase 2 clinical trials, & working to improve the lives of people suffering from cancers of unmet need👉 https://t.co/nFKZoQJHIs

🔗 Receive updates on $PTX: https://t.co/2DO7rEKwF0
#Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

It’s no secret that the rate of cancer both in Australia and overseas appears to be increasing - $PTX is working to improve the lives of people suffering from cancers of unmet need.
Learn more 👉 https://t.co/GymYG3YEx1

🔗 Stay up-to-date on PTX: https://t.co/7bcsqwApoE
#Health

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics $PTX CEO James McDonnell discusses the outstanding Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.
Watch now 👉 https://t.co/XmK3J8whNM

#CellTherapies #CancerTreatment #Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Prescient Therapeutics $PTX has announced the completion of its first U.S. site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL).
Learn more 👉 https://t.co/BAlKfDjuuq

#Biotech #Health #CancerTherapies

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

$PTX CEO James McDonnell chats with @StockheadAU Tylah Tully to discuss the company’s major milestone with the initiation of its first U.S. site for the Phase 2a trial of PTX-100.
Watch now 👉 https://t.co/bMVimyZ86G

#Health #Biotech #CancerTreatments

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

$PTX announces that the first U.S. Site Initiation Visit has been completed.
View 👉 https://t.co/0nmWyWaCEd

This marks a significant milestone in the progress of the Phase 2a trial for PTX-100 for patients suffering with refractory/relapsed Cutaneous T Cell Lymphoma.

#Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

🎧@SmallCapsASX Jess Fertig & $PTX CEO James McDonnell discuss the promising PTX-100 Phase 1b trial results & the designations received from the FDA which could allow Prescient to head toward a US$1.8bn market after Phase 2.
Listen now 👉 https://t.co/2xV0yRcF2f

#Biotech #Health

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Special Report 📣 With a new leadership team and fast-track designation from the US Food and Drug Administration (FDA), clinical-stage oncology company $PTX is laser focused on development of lead compound PTX-100.
Read more👉 https://t.co/2Jg8x1pR0p

#Health #Biotech

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

Join Prescient Therapeutics (ASX: PTX) CEO James McDonnell at the Twilight Investor Briefing hosted by @MonsoonComms this Wednesday, 9th July in Melbourne CBD.
🔗 RSVP now: https://t.co/9CfiMKqJPz

#Biotech #Health

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

$PTX CEO James McDonnell chats with @StockheadAU’s Tylah Tully to discuss the promising PTX-100 Phase 1b trial results, and how the company is working to improve the lives of people suffering from cancers of unmet need. Watch now 👉 https://t.co/DiewDJJPuk

#Biotech #Health

[Prescient Therapeutics PTX, Novel Cancer Therapies @PTX_AUS]

One in five people will get cancer in their lifetime - Prescient Therapeutics $PTX is working to improve the lives of people suffering from cancers of unmet need. Read more 👉 https://t.co/ZUsnEE6eKh

🔗 Stay up-to-date on PTX: https://t.co/sLxqcVAkTb
#Health #CancerTreatments